Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Neovascular age-related macular degeneration

3 evidence topics · 1 source

Global incidence trend, 2006 to 2020

“The incidence of nAMD was 71 (95% CI 55–90) and 102 (95% CI 88–118) per 100,000 person years in 2006 and 2020, respectively.” (opens the source at this quote in a new tab)

Incidence by age group

“In the age group of 75–84 years, the incidence increased 1.2-fold from 300 in 2006 to 366 in 2020.” (opens the source at this quote in a new tab)

“The increase in the age group of 85–96 years was 2.4-fold from 200 in 2006 to 471 in 2020.” (opens the source at this quote in a new tab)

Incidence by sex

“The incidence of nAMD in women was almost two-fold greater compared to males at the same age.” (opens the source at this quote in a new tab)